title: The effects of thromboxane A2 inhibition (picotamide) and angiotensin II receptor blockade (losartan) in primary Raynaud's phenomenon.
abstract: OBJECTIVE
  To assess the role of thromboxane A2 and of angiotensin II in patients with primary Raynaud's phenomenon.
  
  
  METHODS
  After an eight-day run-in period, the patients were enrolled in a single-blind, cross-over, study.
  
  
  METHODS
  Patients were examined at the Ambulatory for Microcirculatory Diseases of the Clinic of Internal Medicine, University Hospital, Verona.
  
  
  METHODS
  Fifteen subjects affected by primary Raynaud's phenomenon were included.
  
  
  METHODS
  A piezoelectric plethysmography to evaluate the distensibility of the digital arteries as the ratio between peak time (PT) and total time (TT), and an oscillometric blood pressure recorder were used after the run-in period, and after a two-week course of picotamide (300 mg b.i.d., i.e. two times daily) or losartan (12.5 mg once daily) with an interval of a week of placebo between the active treatments. The tests were performed after every treatment in basal condition and during mental stress. The patients reported in a diary the number and the severity (from 0 to 4 +) of the vasospastic crises.
  
  
  RESULTS
  The change in TP/TT ratio appeared statistically significant only after losartan treatment, both in basal condition and during mathematical stress. Both pharmacological treatments, with respect to placebo, showed an improvement of the scores, derived from the number and severity of vasospastic attacks, but only the therapy with losartan determined a statistically significant improvement.
  
  
  CONCLUSIONS
  The inhibition of the type 1 receptor for angiotensin II seems highly effective in the reduction of the vasospastic crises in the subjects with primary Raynaud's phenomenon. According to our experience, losartan could be used more extensively in the treatment of these patients besides arterial hypertension.
authors.affiliation: Clinic of Internal Medicine, University of Verona, Italy.
authors.forename: P
authors.initials: P
authors.lastname: Pancera
authors.forename: S
authors.initials: S
authors.lastname: Sansone
authors.forename: S
authors.initials: S
authors.lastname: Secchi
authors.forename: G
authors.initials: G
authors.lastname: Covi
authors.forename: A
authors.initials: A
authors.lastname: Lechi
mesh_terms: D000293:Adolescent; D000328:Adult; D000804:Angiotensin II / Q000378:metabolism*; D057911:Angiotensin Receptor Antagonists; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects; D018592:Cross-Over Studies; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D019808:Losartan / Q000627:therapeutic use*; D008297:Male; D010795:Phthalic Acids / Q000627:therapeutic use*; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D010991:Plethysmography; D011928:Raynaud Disease / Q000188:drug therapy* / Q000503:physiopathology; D016037:Single-Blind Method; D013928:Thromboxane A2 / Q000037:antagonists & inhibitors*; D016896:Treatment Outcome
chemical_list: D057911:Angiotensin Receptor Antagonists; D000959:Antihypertensive Agents; D010795:Phthalic Acids; D010975:Platelet Aggregation Inhibitors; D000804:Angiotensin II; D013928:Thromboxane A2; C011581:picotamide; D019808:Losartan